Exited position

Stanley Druckenmiller’s Vertex Pharmaceuticals (VRTX) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Duquesne Family OfficeVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ2 2012Earliest verified positive filing snapshot
Latest statusExited positionBased on the latest supported relationship state
Peak shares447.57KHighest verified quarter-end share count
Quarters reported3Verified quarters with shares above zero
What happened?

Duquesne Family Office first reported Vertex Pharmaceuticals in Q2 2012. The reported position was reduced across later filings. The latest verified relationship event shows that Duquesne Family Office sold the entire position in Q4 2014, and the stock is no longer reported in the latest verified portfolio.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q4 2014
Sold the entire position−146.60K shares · No shares reported at quarter-end
Q3 2014
New position+146.60K shares · 146.60K shares reported
Filing context

Quarter-end price $112.31 · Estimated holding basis $112.31

Q4 2012
Sold the entire position−223.79K shares · No shares reported at quarter-end
Q3 2012
Sold 50.0% of the position−223.79K shares · 223.79K shares remained
Filing context

Quarter-end price $55.89 · Estimated holding basis $55.92

Q2 2012
New position+447.57K shares · 447.57K shares reported
Filing context

Quarter-end price $55.92 · Estimated holding basis $55.92

Portfolio importance

How important was Vertex Pharmaceuticals in Duquesne Family Office’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Last reported portfolio weight2.0%Q3 2014
Last reported rank#20of 36 reported positions
Peak portfolio weight2.0%Q3 2014
Best historical rank#20Q3 2014
At peak importanceQ3 2014
VRTX
2.0%
Largest holding
12.0%
Cross-investor discovery

Who else owns Vertex Pharmaceuticals?

Also reported by 2 other tracked investors in their latest verified filings.

Ray DalioBridgewater Associates, LP
VRTX0.0% of reported portfolio
Joel GreenblattGotham Asset Management
VRTX0.0% of reported portfolio
Explore Vertex Pharmaceuticals across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$514.632026-09-15

Market context only; not an investor transaction price.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

View Vertex Pharmaceuticals stock page →

This tracker follows Duquesne Family Office LLC’s Form 13F disclosures—not Stanley Druckenmiller’s personal brokerage account. Form 13F reports quarter-end U.S.-listed positions and certain options, but it does not reveal exact trade dates, execution prices, short positions or the purpose of an option position.